Skip to main content
Top
Published in: Clinical Rheumatology 6/2013

01-06-2013 | Original Article

Impact of managed care health insurance system for indigent patients with rheumatoid arthritis in Puerto Rico

Authors: Yesenia Santiago-Casas, Tania González-Rivera, Lesliane Castro-Santana, Grissel Ríos, David Martínez, Vanessa Rodríguez, Rafael González-Alcover, Ángel M. Mayor, Luis M. Vilá

Published in: Clinical Rheumatology | Issue 6/2013

Login to get access

Abstract

The aim of this study was to determine the clinical outcome among indigent patients with rheumatoid arthritis (RA) in Puerto Rico receiving their healthcare in a managed care system, as compared with non-indigent patients treated in fee-for-service settings. A cross-sectional study was conducted in 214 Puerto Ricans with RA (per American College of Rheumatology classification criteria). Demographic features, health-related behaviors, cumulative clinical manifestations, disease activity (per disease activity score 28), comorbid conditions, functional status (per Health Assessment Questionnaire), and pharmacologic profile were determined. Data were examined using uni- and multivariable (logistic regression) analyses. The mean (standard deviation (SD)) age of the study population was 56.6 (13.5) years; 180 (84.1 %) were women. The mean (SD) disease duration was 10.8 (9.6) years. Sixty-seven patients were treated in the managed care setting, and 147 patients received their healthcare in fee-for-service settings. In the multivariable analyses, RA patients treated in the managed care setting had more joint deformities, extra-articular manifestations, arterial hypertension, type 2 diabetes mellitus, cardiovascular events, fibromyalgia syndrome, and poorer functional status while having a lower exposure to biological agents than those treated in fee-for-service settings. Efforts should be undertaken to curtail the gap of health disparities among these Hispanic patients in order to improve their long-term outcomes.
Literature
1.
go back to reference Weissman JS, Stern R, Fielding SL, Epstein AM (1991) Delayed access to health care: risk factors, reasons, consequences. Ann Intern Med 114:325–331PubMedCrossRef Weissman JS, Stern R, Fielding SL, Epstein AM (1991) Delayed access to health care: risk factors, reasons, consequences. Ann Intern Med 114:325–331PubMedCrossRef
2.
go back to reference Pappas G, Queen S, Hadden W, Fisher G (1993) The increasing disparity in mortality between socioeconomic groups in the United States, 1960 and 1986. N Engl J Med 329:103–109PubMedCrossRef Pappas G, Queen S, Hadden W, Fisher G (1993) The increasing disparity in mortality between socioeconomic groups in the United States, 1960 and 1986. N Engl J Med 329:103–109PubMedCrossRef
3.
go back to reference Brekke M, Hjortdahl P, Thelle DS, Kvien TK (1999) Disease activity and severity in patients with rheumatoid arthritis: relations to socioeconomic inequality. Soc Sci Med 48:1743–1750PubMedCrossRef Brekke M, Hjortdahl P, Thelle DS, Kvien TK (1999) Disease activity and severity in patients with rheumatoid arthritis: relations to socioeconomic inequality. Soc Sci Med 48:1743–1750PubMedCrossRef
4.
go back to reference McEntegart A, Morrison E, Capell HA et al (1997) Effect of social deprivation on disease severity and outcome in patients with rheumatoid arthritis. Ann Rheum Dis 56:410–413PubMedCrossRef McEntegart A, Morrison E, Capell HA et al (1997) Effect of social deprivation on disease severity and outcome in patients with rheumatoid arthritis. Ann Rheum Dis 56:410–413PubMedCrossRef
5.
go back to reference Harrison MJ, Tricker KJ, Davies L et al (2005) The relationship between social deprivation, disease outcome measures, and response to treatment in patients with stable, long-standing rheumatoid arthritis. J Rheumatol 32:2330–2336PubMed Harrison MJ, Tricker KJ, Davies L et al (2005) The relationship between social deprivation, disease outcome measures, and response to treatment in patients with stable, long-standing rheumatoid arthritis. J Rheumatol 32:2330–2336PubMed
6.
go back to reference Maiden N, Capell HA, Madhok R, Hampson R, Thomson EA (1999) Does social disadvantage contribute to the excess mortality in rheumatoid arthritis patients? Ann Rheum Dis 58:525–529PubMedCrossRef Maiden N, Capell HA, Madhok R, Hampson R, Thomson EA (1999) Does social disadvantage contribute to the excess mortality in rheumatoid arthritis patients? Ann Rheum Dis 58:525–529PubMedCrossRef
7.
go back to reference Alegría M, McGuire T, Vera M, et al (2001–2002) The impact of managed care on the use of outpatient mental health and substance abuse services in Puerto Rico. Inquiry 38:381–95. Alegría M, McGuire T, Vera M, et al (2001–2002) The impact of managed care on the use of outpatient mental health and substance abuse services in Puerto Rico. Inquiry 38:381–95.
8.
go back to reference Hulme PA, Rios H (1998) Healthcare reform in Puerto Rico. Managed care in a unique environment. J Nurs Adm 28:44–49PubMed Hulme PA, Rios H (1998) Healthcare reform in Puerto Rico. Managed care in a unique environment. J Nurs Adm 28:44–49PubMed
9.
go back to reference Marín HA, Ramírez R, Wise PH, Peña M, Sánchez Y, Torres R (2009) The effect of Medicaid managed care on prenatal care: the case of Puerto Rico. Matern Child Health J 13:187–197PubMedCrossRef Marín HA, Ramírez R, Wise PH, Peña M, Sánchez Y, Torres R (2009) The effect of Medicaid managed care on prenatal care: the case of Puerto Rico. Matern Child Health J 13:187–197PubMedCrossRef
10.
go back to reference Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMedCrossRef Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMedCrossRef
11.
go back to reference Grundy SM, Cleeman JI, Daniels SR et al (2005) American Heart Association/National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112:2735–2752PubMedCrossRef Grundy SM, Cleeman JI, Daniels SR et al (2005) American Heart Association/National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112:2735–2752PubMedCrossRef
12.
go back to reference Fransen J, van Riel PL (2005) The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol 23:S93–A99PubMed Fransen J, van Riel PL (2005) The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol 23:S93–A99PubMed
13.
go back to reference Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F (1992) The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 35:498–502PubMedCrossRef Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F (1992) The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 35:498–502PubMedCrossRef
14.
go back to reference Yelin EH, Shearn MA, Epstein WV (1986) Health outcomes for a chronic disease in prepaid group practice and fee for service settings. The case of rheumatoid arthritis. Med Care 24:236–247PubMedCrossRef Yelin EH, Shearn MA, Epstein WV (1986) Health outcomes for a chronic disease in prepaid group practice and fee for service settings. The case of rheumatoid arthritis. Med Care 24:236–247PubMedCrossRef
15.
go back to reference Ward MM, Lubeck D, Leigh JP (1998) Longterm health outcomes of patients with rheumatoid arthritis treated in managed care and fee-for-service practice settings. J Rheumatol 25:641–649PubMed Ward MM, Lubeck D, Leigh JP (1998) Longterm health outcomes of patients with rheumatoid arthritis treated in managed care and fee-for-service practice settings. J Rheumatol 25:641–649PubMed
16.
go back to reference Solomon A, Christian BF, Dessein PH, Stanwix AE (2005) The need for tighter rheumatoid arthritis control in a South African public health care center. Semin Arthritis Rheum 35:122–131PubMedCrossRef Solomon A, Christian BF, Dessein PH, Stanwix AE (2005) The need for tighter rheumatoid arthritis control in a South African public health care center. Semin Arthritis Rheum 35:122–131PubMedCrossRef
17.
go back to reference Dessein PH, Christian BF, Woodiwiss AJ, Norton GR, Solomon A (2010) Public healthcare attendance associates with enhanced conventional and non-conventional atherosclerotic cardiovascular disease risk burdens in established rheumatoid arthritis. Clin Exp Rheumatol 28:230–237PubMed Dessein PH, Christian BF, Woodiwiss AJ, Norton GR, Solomon A (2010) Public healthcare attendance associates with enhanced conventional and non-conventional atherosclerotic cardiovascular disease risk burdens in established rheumatoid arthritis. Clin Exp Rheumatol 28:230–237PubMed
18.
go back to reference Yazici Y, Kautiainen H, Sokka T (2007) Differences in clinical status measures in different ethnic/racial groups with early rheumatoid arthritis: implications for interpretation of clinical trial data. J Rheumatol 34:311–315PubMed Yazici Y, Kautiainen H, Sokka T (2007) Differences in clinical status measures in different ethnic/racial groups with early rheumatoid arthritis: implications for interpretation of clinical trial data. J Rheumatol 34:311–315PubMed
19.
go back to reference Bruce B, Fries JF, Murtagh KN (2007) Health status disparities in ethnic minority patients with rheumatoid arthritis: a cross-sectional study. J Rheumatol 34:1475–1479PubMed Bruce B, Fries JF, Murtagh KN (2007) Health status disparities in ethnic minority patients with rheumatoid arthritis: a cross-sectional study. J Rheumatol 34:1475–1479PubMed
20.
go back to reference Young A, Koduri G (2007) Extra-articular manifestations and complications of rheumatoid arthritis. Best Pract Res Clin Rheumatol 21:907–927PubMedCrossRef Young A, Koduri G (2007) Extra-articular manifestations and complications of rheumatoid arthritis. Best Pract Res Clin Rheumatol 21:907–927PubMedCrossRef
21.
go back to reference Turesson C, McClelland RL, Christianson TJ, Matteson EL (2006) Multiple extra-articular manifestations are associated with poor survival in patients with rheumatoid arthritis. Ann Rheum Dis 65:1533–1534PubMedCrossRef Turesson C, McClelland RL, Christianson TJ, Matteson EL (2006) Multiple extra-articular manifestations are associated with poor survival in patients with rheumatoid arthritis. Ann Rheum Dis 65:1533–1534PubMedCrossRef
22.
go back to reference Ruiz-Esquide V, Gómez-Puerta JA, Cañete JD et al (2011) Effects of smoking on disease activity and radiographic progression in early rheumatoid arthritis. J Rheumatol 38:2536–2539PubMedCrossRef Ruiz-Esquide V, Gómez-Puerta JA, Cañete JD et al (2011) Effects of smoking on disease activity and radiographic progression in early rheumatoid arthritis. J Rheumatol 38:2536–2539PubMedCrossRef
23.
go back to reference Saevarsdottir S, Wedrén S, Seddighzadeh M (2011) Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts. Arthritis Rheum 63:26–36PubMedCrossRef Saevarsdottir S, Wedrén S, Seddighzadeh M (2011) Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts. Arthritis Rheum 63:26–36PubMedCrossRef
24.
go back to reference Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D (2012) Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 71:1524–1529PubMedCrossRef Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D (2012) Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 71:1524–1529PubMedCrossRef
25.
go back to reference Marmot MG, Bosma H, Hemingway H, Brunner E, Stansfeld S (1997) Contribution of job control and other risk factors to social variations in coronary heart disease incidence. Lancet 350:235–239PubMedCrossRef Marmot MG, Bosma H, Hemingway H, Brunner E, Stansfeld S (1997) Contribution of job control and other risk factors to social variations in coronary heart disease incidence. Lancet 350:235–239PubMedCrossRef
26.
27.
go back to reference Karpouzas GA, Dolatabadi S, Moran R, Li N, Nicassio PM, Weisman MH (2012) Correlates and predictors of disability in vulnerable US Hispanics with rheumatoid arthritis. Arthritis Care Res 64:1274–1281CrossRef Karpouzas GA, Dolatabadi S, Moran R, Li N, Nicassio PM, Weisman MH (2012) Correlates and predictors of disability in vulnerable US Hispanics with rheumatoid arthritis. Arthritis Care Res 64:1274–1281CrossRef
28.
go back to reference Wolfe F, Cathey MA, Kleinheksel SM (1984) Fibrositis (Fibromyalgia) in rheumatoid arthritis. J Rheumatol 11:814–818PubMed Wolfe F, Cathey MA, Kleinheksel SM (1984) Fibrositis (Fibromyalgia) in rheumatoid arthritis. J Rheumatol 11:814–818PubMed
29.
go back to reference Yelin EH, Trupin LS, Katz PP (2005) Impact of managed care on the use of biologic agents for rheumatoid arthritis. Arthritis Rheum 53:423–430PubMedCrossRef Yelin EH, Trupin LS, Katz PP (2005) Impact of managed care on the use of biologic agents for rheumatoid arthritis. Arthritis Rheum 53:423–430PubMedCrossRef
30.
go back to reference Quinn MA, Conaghan PG, O'Connor PJ et al (2005) Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 52:27–35PubMedCrossRef Quinn MA, Conaghan PG, O'Connor PJ et al (2005) Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 52:27–35PubMedCrossRef
31.
go back to reference Fajardo Hermosillo LD, Mayor AM, Franco AE MD, Morell CA, Román YM, Vilá LM (2010) Malignancy in a Hispanic population with rheumatoid arthritis. Ann Rheum Dis 69(Suppl3):370 Fajardo Hermosillo LD, Mayor AM, Franco AE MD, Morell CA, Román YM, Vilá LM (2010) Malignancy in a Hispanic population with rheumatoid arthritis. Ann Rheum Dis 69(Suppl3):370
32.
go back to reference Lubeck DP (2001) A review of the direct costs of rheumatoid arthritis: managed care versus fee-for-service settings. PharmacoEconomics 19:811–818PubMedCrossRef Lubeck DP (2001) A review of the direct costs of rheumatoid arthritis: managed care versus fee-for-service settings. PharmacoEconomics 19:811–818PubMedCrossRef
Metadata
Title
Impact of managed care health insurance system for indigent patients with rheumatoid arthritis in Puerto Rico
Authors
Yesenia Santiago-Casas
Tania González-Rivera
Lesliane Castro-Santana
Grissel Ríos
David Martínez
Vanessa Rodríguez
Rafael González-Alcover
Ángel M. Mayor
Luis M. Vilá
Publication date
01-06-2013
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 6/2013
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-013-2167-9

Other articles of this Issue 6/2013

Clinical Rheumatology 6/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine